WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Remdesivir: A Critical Review of Pharmacology and Clinical Efficacy to Treat Covid 19

***Sumit P. Isane[1], Santosh A. Waghmare[2], Hemant V. Kamble[3]***

[1]Student, Department of Pharmaceutics,
[2]Professor, Department of Pharmacy,
[3]Principal, Loknete Shri Dadapatil Pharate College of Pharmacy, MandavganPharata, Shirur, Pune, Maharashtra, India.
**DOI**: https://doi.org/10.55248/gengpi.2023.4130

**Abstract-**

The global pandemic of SARS- CoV- 2, the causative viral pathogen of COVID- 19, has driven the biomedical community to action to uncover and develop antiviral interventions. One implicit remedial approach presently being estimated in multitudinous clinical trials is the agent remdesivir, which has endured a long and winding experimental path. Remdesivir as a medicine attracted a veritably serious consideration of whole Globe in treatment of the epidemic complaint COVID- 19. More lately published in- vitro inhibition exertion and in- vivo case studies were showing promising clinical results and outgrowth of effective inhibition of SARS- CoV- 2 contagion by the use of remdesivir. Still at the same time, use of the remdesivir showed substantial mischievous adverse events in cases which needs a special attention during treatment course of COVID- 19. Therefore, the use of remdesivir in treatment of COVID- 19 is having current transnational interest although some further clinical attestations are still necessary in order to understand the factual effectiveness and medium of remdesivir against COVID- 19.. Ok n this review composition, we give an overview of remdesivir's discovery, Pharmacology including medium of action, and The Current Studies Exploring Its Clinical Effectiveness.

**Keywords**:- Remdesivir; Covid-19; Remdesivir Pharmacology; Sars-Cov-2 Virus, Clinical Efficacy, Clinical Trials.

## Introduction

Covid- 19 Is The Acronym That's Used For The New Coronavirus Disease- 2019, Which Is Caused Due To Recently Arising Delta- Coronavirus Named As Sars- Cov- 2. The First Case Of Covid- 19 Was Appeared In December 2019 In Wuhan Megacity Of Hubei Fiefdom Demitasse And By February 2020, It's Declared As Global Pandemic With The Public Health Exigency Due To Its Further Contagious Nature Than That Of Sars- Cov And Mers- Cov.[1,2]

Worldwide, Over 131 Million People Have Been Diagnosed With Coronavirus Disease 2019( Covid- 19), Performing In Nearly2.9 Million Deaths. As A Global Pandemic, It Has Redounded In A Profound, Negative Impact On The Healthcare System, Frugality And Fiscal Requests Due To The Public Health Extremity, Loss Of Life, Reduced Productivity, Business Closures, Trade Dislocation, And Desolation Of The Tourism Assiduity. Healthcare Systems Worldwide Are Now Passing Varying Situations Of Stress Amid Infection Rates That Demand A Collaborative Response. Several Remedial Agents Have Been Estimated For The Treatment Of Covid- 19 In An Attempt To Control Viral Replication. These Involve Colorful Approaches, Similar As The Antiviral Repurposing Of Medicines That Were Used In Severe Acute Respiratory Pattern( Sars)- Cov- 1 And Mers( Middle East Respiratory Pattern)- Cov, Including Antiretroviral Agents; Using Immunoglobulins And Convalescent Tube; And The Bioinformatics Webbing Of Chemical Libraries For Being Composites Medicines That Are Likely To Act On Sarscov- 2. Multiple Antiviral Treatment Options Are Under Disquisition For Covid- 19 Infections, Including Remdesivir, Which Was First Developed For The Treatment Of Ebola Infection. Remdesivir Is A Nucleotide Prodrug That's Metabolised Intracellularly To The Active Nucleoside Triphosphate( Atp) And Interferes With Viral Rna-Dependent Rna Polymerase Exertion. This Exertion Led To Its Use In Cases With Sars- Cov- 2 Infection( Covid- 19), In The Absence Of Any Effective Treatment. Still, The Pharmacology And Pharmacokinetics Of Remdesivir Within The Respiratory Tract And Other Infected Organs Of Critically Ill Cases With Covid- 19 Remain Largely Unknown. Safety Information Is Presently Broken And Limited [3-10].

Coronaviruses Primarily Cause Respiratory And Intestinal Infections In Animals And Humans. Discovered In The 1960s, They Were Firstly Allowed To Be Only Responsible For Mild Condition, With Strains Similar As Hcov 229e And Hcov Oc43 Responsible For The Common Cold. That Changed In 2003 With The Sars Pandemic And In 2012 With The Outbreak Of Mers, Both Zoonotic Infections That Affected In Mortality Rates Lesser Than 10 And 35, Independently.4 Both Coronaviruses Likely Surfaced From Native Bat Populations, Which Maintain A Broad Diversity Of Coronaviruses, And Were Transmitted Through An Intermediate Host To Humans. Loss Of Natural Habitat And Increased Exposure To New Hosts Are Likely Responsible For The Increased Frequence Of Zoonotic Infections Forming From Batons. Substantiation Also Supports That The New Coronavirus

Which Surfaced In The Wuhan Region Of China In Late 2019 Also Began From Batons. This Novel Coronavirus, Sars- Cov- 2, Affected In An Outbreak Of Pathogenic Viral Pneumonia In Wuhan, Hubei Province, China, As Reported To The World Health Organization( Who) In December 2019. Posterior This Composition Not Subject Tou.S. Brand. Published 2020 By The American Chemical Society Spread Has Led To A Global Pandemic( Officially Declared By The Who On March 11, 2020) .[11-17]




*Figure 1. Life Cycle Of Sars-Cov-2 In Host Cells. Sars-Cov-2 Primarily Infects The Respiratory Tract (Nasal Epithelial Cells, Pneumocytes, And Alveolar Macrophages) And The Gastrointestinal Tract (Enterocytes). The Virus Enters Though Direct Interaction Between The Viral S Protein And The Cellular Receptor Angiotensin-Converting Enzyme 2 (Ace2). Following Entry, The Viral Genome Is Released And Translated Into The Viral Replicase Polyproteins Pp1a And Pp1ab, Which Are Cleaved Into Functional Proteins By Viral Proteases.2 Viral Genome Replication Is Mediated By The Viral Replication Complex, Including The Rna-Dependent Rna Polymerase (Rdrp). Viral Nucleocapsids Are Assembled From The Packaged Viral Genomes And Translated Viral Structural Proteins And Released Through Exocytosis. Potential Targets And Postulated Mechanism Of Action For Antiviral Interventions Are Shown: Blocking Virus/Host Cell Interaction Through The Use Of Antibodies/Nanobodies (And Convalescent Plasma Therapy) Or Recombinant Ace2 Protein; Use Of Hydroxychloroquine (Based On In Vitro Data) To Inhibit Endosome Maturation; Use Of Protease Inhibitors To Inhibit Viral/Endosome Membrane Fusion Or Viral Polypeptide Maturation; Nucleoside/Nucleotide Analogues To Inhibit Viral Genome Replication.*

## Pharmacokinetics Of Remdesivir

Remdesivir Is Developed By Gilead Medicinal In 2009 To Treat The Hepatitis, Which Displayed Poor To Moderate Antiviral Energy Against Hepatitis. Farther Exploration Literature Reportedanti-Viral Use Of Remdesivir Against Colorful Coronaviruses Similar Mers- Cov, Sars- Cov, Δcorronaviruses Family. Hepatitis C Virus, Nipah, Marburg, Enterovirus, Filo-, Pneumo-, And Paramyxo- Viruses Etc. Remdesivir Wasre-Pitched By The Gilead Medicinals For Treatment Of Ebola In 2014 Which Displayed Effective Exertion Against The Ebola Virus And Used Extensively Against Ebola Virus Epidemic. Further In Recent Scenario, Remdesivir Is Used To Treat Against Covid- 19 Which May Have Possesses Side Goods. Besides This, Remdesivir May Be Considered As A Safer Medicine Than That Of Hydroxychloroquine Since, Partial Life Of Remdesivir Is Much Lower As Compared To That Of Hydroxychloroquine( Table 1, Entry 1). Nearly 21 Hydroxychloroquine In Body Remained Unchanged While That Of Remdesivir Is Just Only 10( Table 1, Entry 2). Remdesivir Showed Quickly Concurrence Due To Its Poor Hepatic Stability And Hence Recommended

***Table 1:***

| Property | Hydroxychloroquine | Remdesivir |
|---|---|---|
| Half-life time | 537 hours [24] | 20 hours [23] |
| Route of elimination | ~40-50% by renally, ~16-21% unchanged, ~2 5% sloughed off in skin ~24-25% through feces [24,25] | ~74% eliminated in urine, ~10% is unchanged, ~18% eliminated in feces [26,27] |
| Absorption and clearance | Absorption in Plasma and distributed in cell [24, 28], 96 mL/min [29] | Poor hepatitis stability, hence faster clearance ater administrated via IV [30] |
| Metabolites | Desethylhydroxychloroquine [28] | Triphosphate metabolite [15,23] |
| Drug interaction | Hydroxychloroquine showed severe drug interaction [1,24] | Drug interaction not known or not available [27] |
| Toxicity | Headache, cardiovascular events, QT prolongation, conduction disorders, ventricular tachycardia and retinopathy etc. [1] | Not well reported in literature, while Encephalopathy is reported by similar analogues drug [31] |

***Pharmacological Properties Of Hydroxychloroquine And Remdesivi***r

Via Iv Administration( Table 1, Entry 3). Remedesivir Showed Less Dangerous Metabolites( Triphosphate) Than That Of Hydroxychloroquine( Desethylhydroxychloroquine)( Table 1, Entry 4). Medicine Commerce And Colorful Deleterious Side Goods Are Veritably Well Known About Hydroxychloroquine Which Involves The Headache, Cardiovascular Events, Qt Extension, Conduction Diseases, Ventricular Tachycardia And Retinopathy Etc( Table 1, Entries,6), Still, Side Goods Of The Remdesivir Aren't Well Given Available Except To That Of Encephalopathy Which Is Shown By Acyclovir A Nucleoside Analogue Analogous To That Of Remdesivir. More Lately, The Fda Emergency Use Authorization Suggests A Loading Cure Of 200 Mg( 5 Mg/ Kg) Formerly In A Day In Cases ⩾ 40 Kg And 100 Mg From Day 2(2.5 Mg/ Kg) .[18-34]

## Mechanism Of Action Of Remdesivir

Remdesivir Is An Antiviral Class Medicine Which Is Phosphoramidate Prodrug Of An Adenosine C- Nucleoside By Entry Into Respiratory Epithelial Cells In The Mortal Body, The Prodrug May Be Efficiently Metabolized To A Nucleoside Triphosphate As An Active Form. The Active Form Can Help The Replication Of Several Coronaviruses In The Lung Epithelial Cells. The Nucleoside Analog Medicine Inhibits The Rna-Dependent Rna Polymerase( Rdrp) By Contending With The Usual Counterpart Adenosine Triphosphate( Atp). The Nucleoside Analog Is Incorporated Into The Generating Rna Strand And Causes A Delayed Stop In The Viral Replication Process As The Enzyme Incorporates One, Two Or Three Further Nucleotides, The Incorporated Nucleoside Analog Moves Back. The Medicine Blocks The Enzyme While It Reaches Into The Third Position Down From The Enzyme's Active Point. It Crashes Into A Conserved Serine( Ser) In The Active Point Of The Enzyme And Inhibits The Enzyme From Moving One Step Forward To Incorporate The Coming Nucleotide. The Exoribonuclease Of The Contagion That Generally Proofreads And Corrects The Replication Errors Can Not Work Against The Activ Form Of Remdesivir .[22,27,35,36]




***Figure 2:- Mechanisms Of Action Of Remdesivir. Remdesivir Is Incorporated Into Cells And Metabolized Into The Nucleoside Triphosphate Analog Form (Active Form) Via A Sequence Of Steps. The Nucleoside Analog Drug Is Used By The Viral Rdrp And Inhibits The Enzyme By Competing With The Usual Counterpart Adenosine Triphosphate (Atp). The Nucleoside Analog Is Incorporated Into The Generating Rna Strand And Causes A Delayed Stop In The Viral Replication Process.***

## Clinical Efficacy Of Remdesivir To Treat Covid-19

Knowledge About The Implicit Efficacity Of Remdesivir Against Coronaviruses Is Confined To In Vitro Studies And Beast Models; Still, Information Related To Covid- 19 Is Speedily Growing . [37]

In January 2020, A 35- Time-Old Manly Infected With Covid- 19 Was Compassionately Treated With Intravenous Remdesivir After Developing Pneumonia In The Usa. The Case Was Rehabilitated For Further Than 12 Days, Intravenous Remdesivir Was Conducted For 7 Days And The Case's Condition Was Supposedly Improved On The Eighth Day. No Adverse Effect Associated With Administration Of Remdesivir Was Reported. [39]

Before The Clinical Trials Are Completed, Information About Using Remdesivir For Covid- 19 Can Be Acquired From Studies On Compassionate Use Of The Medicine. At Present, Several Anecdotal Reports On Remdesivir Administration To Treat Covid- 19 Cases Are Available. A Recent Review Composition Reported That Using Remdesivir To Treat 17 Passengers On The Diamond Princess Voyage Boat For 10 Days Resulted In The Cases ' Survival. Administration Of The Remedial Led To Lower Dependence Of The Cases On A Ventilator. Still, It Should Be Noted That Similar Reports Can Not Be Considered References For Any Conclusions. [37]

A Preprint Reported New Medical Exploration On The First 12 Covid- 19 Cases In The Usa; Still, Authors Indicated That The Study Has Yet To Be Estimated And So Shouldn't Be Employed To Guide Clinical Practice. In The Report, Demographic And Clinical Information Of The Subjects, Data On Course Of Infection And Clinical Care Were Interpreted. Seven Of 12 Cases( 58) With Radiographic Signs Of Pneumonia And Clinical Or Laboratory Suggestions Of Worsening In The Alternate Week Of The Infection Were Rehabilitated. Three Rehabilitated Cases Entered Investigational Antiviral Remdesivir For 4 To 10 Days. In All Cases, Following Remdesivir Launch, Aminotransferase Situations Were Elevated And Temporary Abdominal Symptoms Including Nausea, Vomiting, Gastroparesis Or Rectal Hemorrhage Were Observed. Nopost-Remdesivir Symptom Was Detected. After Recovery Of The Respiratory Symptoms, The Medicine Was Stopped. [40]

In 2020, In A Published Study In New England Journal Of Medicine, Remdesivir Was Handed On A Compassionate- Use Base To Cases With Severe Covid- 19. Cases With VerifiedSars- Cov- 2 Infection And Breathing Oxygen Support Or Entering Ambient Air Were Included In The Study. The Oxygen Achromatism Of The Subjects Was 94 Or Lower. The Medicine Was Conducted For 10 Days. At The First Day, The Cases Entered 200 Mg Of The Medicine Intravenously, And 100 Mg Of Remdesivir Was Daily Used In The Remaining 9 Days Of The Treatment Course. Among 53 Cases Included In The Cohort Study, Clinical Enhancement Was Observed In 36 Subjects( 68). Data For Some Cases Included In The Study Were Preliminarily Described.[39,41-43]

Beigel Et Al( 2020) Conducted A Double-Eyeless, Randomized, Placebo- Controlled Trial On Intravenous Remdesivir In Cases With Covid- 19. Cases Were Aimlessly Divided Into Treatment And Placebo Groups Entering Remdesivir For Over To 10 Days. The Time Of Recovery In The Cases Who Entered Remdesivir Was Shorter Than That Of The Placebo Group(Clinicaltrials.Gov Number Nct04280705). [44]

Goldman Et Al (2020) Did A Randomized, Open-Label, Phase 3 Trial Including Hospitalized Patients With Covid-19. Patients Were Randomly Divided To Receive 5-Day And 10-Day Courses Of The Intravenous Remdesivir. In Patients With Severe Covid-19 Not Needing Mechanical Ventilation, There Was Not Any Significant Difference Between The 5-Day And 10-Day Durations Of The Intravenous Remdesivir. Due To Lack Of A Placebo Control, The Degree Of Benefit Cannot Be Ascertained (Clinicaltrials. Gov Number: Nct04292899). [38]

Wang Et Al (2020) Conducted A Randomized, Double- Blind, Placebo-Controlled, Multicenter Trial In Adult Patients With Covid-19 At Ten Hospitals In China (Clinicaltrials. Gov Number: Nct04257656). The 237 Patients Were Randomly Divided Into The Remdesivir (158 Cases) And Placebo Groups (79 Cases). Results Showed That Remdesivir Administration Is Not Related To A Significant Change In The Time Of Clinical Improvement. However, Patients Who Received Remdesivir Had A Numerically Shorter Recovery Time Compared To Those Who Received Placebo.[45]

## Clinical Trials

Several Clinical Trials Of Intravenous Remdesivir To Treat Covid- 19 Are Ongoing. A Double-Blindfolded, Placebo- Controlled Trial(Clinicaltrials.Gov Identifier Nct04280705) Is Underway In The Usa In Which Cases Are Aimlessly Divided Into Two Placebo And Remdesivir Groups. In The Remdesivir Group, Cases Admit 200 Mg Of Parenteral Remdesivir As An Original Cure On The First Day, And A Conservation Cure Of The Medicine( 100 Mg Formerly- Diurnal) While Rehabilitated For Over To 10days.The Primary Outgrowth Of The Trial Is Time To Recovery. Day Of Recovery Is The First Day On Which The Case Satisfies One Of The Following Three Orders From The Ordinal Scale 1) Rehabilitated, Not Demanding Supplemental Oxygen – No Longer Needs Ongoing Medical Care; 2) Not Rehabilitated, Limitation On Conditioning And/ Or Demanding Home Oxygen; And 3) Not Rehabilitated, No Limitations On Conditioning. The Ordinal Scale Is An Assessment Of The Clinical Status At The First Assessment Of A Given Study Day. The Us National Library Of Medicine Clinical Trials Registry Described The Seven Order Scale As Follows Death, Rehabilitated/ On Invasive Mechanical Ventilation Or Ecmo, Rehabilitated/ On Noninvasive Ventilation Or High- Inflow Oxygen Bias, Rehabilitated/ Necessitating Supplemental Oxygen, Rehabilitated Not Demanding Supplemental Oxygen, Not Rehabilitated/ Limited Exertion, Not Rehabilitated No Limitations.[46- 48]

A Randomized, Phase 3 Clinical Trial Of 5 Versus 10 Days Of Remdesivir, Sponsored By Gilead Lores, Is Enrolling Cases With Severe Covid-19(Clinicaltrials.Gov Identifier Nct04292899). Primary Issues Are The Odds Of Rate For Enhancement On A Seven- Point Ordinal Scale On Day 14. Another Phase 3, Randomized Trial Of Remdesivir(Clinicaltrials.Gov Identifier Nct04292730) Is The Same As Nct04292899 Except Cases Enrolling In That Study Suffer Moderate Covid- 19. The Primary Outgrowth Is The Proportion Of Subjects Discharged By Day 11.[48.49]

Two Double-Blindfolded, Placebo- Controlled Trials Retaining In China Were Designed To Estimate The Efficacity And Safety Of Intravenousremdesivir.OneTrial(Clinicaltrials.Gov Identifier Nct04252664) Targets 308 Hospitalized Grown-Ups With Mild- To-Moderate Covid- 19 And Another Trial(Clinicaltrials.Gov Identifier Nct04257656) Targets 452 Hospitalized Grown-Ups With Severe Covid- 19. In Both Trials, In A 10-Day Authority, The Original Cure Of Remdesivir Is 200 Mg On Day 1, Followed By 100 Mg Formerly- Diurnal For Remaining Days.,40 In Both Trials, The Primary Outgrowth Measure Is The Time To Clinical Recovery. The Time To Clinical Recovery Is Defined As The Time( In Hours) From The Launch Of Study Drug( Active Or Placebo) Until Normalization Of Fever, Respiratory Rate, Oxygen Saturation And Relief Of Cough, Sustained For At Least 72 H, Or Live Sanitarium Discharge, Whichever Comes First.[50,51]

At This Time, There Are Ten Registered Clinical Trials To Investigate The Efficacy And/Or Safety Of Remdesivir For Covid-19 (Table 2).

| Registration Number | Official Title | Status | Country | Estimated Study Completion Date |
|---|---|---|---|---|
| NCT04257656 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with severe COVID-19 | Terminated | China | April 10, 2020 |
| NCT04365725 | A multicenter, retrospective study of the effects of remdesivir in the treatment of severe COVID-19 infections | Recruiting | France | June 2020 |
| NCT04302766 | An intermediate-size patient population expanded access treatment protocol for coronavirus disease 2019 (COVID-19) using remdesivir (RDV; GS-5734™) | Available | – | – |
| NCT04252664 | A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate COVID-19 | Suspended | China | April 27, 2020 |
| NCT04323761 | Expanded access treatment protocol: remdesivir (RDV; GS-5734) for the treatment of SARS-CoV-2 (CoV) infection | Available | – | – |
| NCT04410354 | A phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of oral merimepodib in combination with intravenous remdesivir in adult patients with advanced coronavirus disease 2019 (COVID-19) | Recruiting | USA | August 2020 |
| NCT04292730 | A phase 3, randomized study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe COVID-19 | Active, not recruiting | – | June 2020 |
| NCT04409262 | A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with severe COVID-19 pneumonia | Recruiting | – | July 31, 2020 |
| NCT04431453 | A phase 2/3, single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of remdesivir (GS-5734™) in participants from birth to <18 years of age with COVID-19 | Not yet recruiting | – | December 2020 |
| NCT04330690 | A multicenter, adaptive, randomized, open-label, controlled clinical trial of the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients (CATCO: Canadian Treatments for COVID-19), in conjunction with the Public Health Emergency SOLIDARITY Trial (World Health Organization) | Recruiting | Canada | May 18, 2022 |

***Table 2:- Registered Clinical Trials To Investigate The Efficacy And/Or Safety Of Remdesivir For Covid-19***

## Conclusion

In Conclusion, Remdesivir Pro-Drug( Gs- 5734) Can Be Effectively Used In The Treatment Of Viral Infections. Use Of This Pro-Drug Basically Offers Active Form Remdesivir( Gs441524) Metabolites Into The Cytoplasm. This Metabolite Intrude The Rna Replication Process Of The Sars- Cov- 2 Contagion Via Objectification In The Viral Inheritable Material Synthesis Process And Stops The Reduplication Of New Contagion Particles. Likewise, In- Vitro Analysis Study Showed Significant Reduction Of The Viral Cargo By Use Of Remdesivir Which Supports The Remedial Use Of Remdesivir Against The Sarscov- 2 Contagion Infection. In- Vivo Analysis Also Demonstrated The Significant Part Of The Remdesivir In Treatment Covid- 19 With Some Adverse Events. Still Precautionary Use Of The Remdesivir Needs Some Further Attention In Remedial Use. Therefore The Use Of Remdesivir Against Covid- 19 Is Having Great Transnational Interest Which Needs Further Further Supporting Attestations To Use Remdesivir Efficiently In Common Practicing To Cure Covid- 19.

**Reference**


1) Badgujar Kc, Badgujar Ab, Patil Vp, DhangarDv. Hydroxychloroquine For Covid-19: A Review And A Debate Based On Available Clinical Trials/Case Studies. Jddt [Internet]. 15may2020 [Cited 13jul.2020];10(3):304-11. Available From: Http://Jddtonline.Info/Index.Php/Jddt/Article/View/4110

2) Badgujar Kc, Patil Dv, DhangarDv, Patil Vp, BadgujarAb.Covid-19: Epidemiology, Clinical Characteristics And Potential Possible Treatment Based On Available Studies, Revision Submitted Manuscript, Coronaviruses Journal, Bentham Science Publication

3) World Health Organization. Coronavirus Disease-19 (Covid-19) Dashboard. 2021. Https:// Covid 19. Who. Int/. Accessed 1 Feb 2021.

4) World Health Organization. Coronavirus Disease-2019 (Covid19) Situation Report. 2021. Https:// Www. Who. Int/ EmergEncies/ DiseaSes/ Novel- CoronAvirus- 2019/ SituaTion- Repor Ts. Accessed 3 Feb 2021.

5) World Health Organization. Events As They Happen. Rolling Updates On Coronavirus Disease-19 (Covid-19). Geneva: World Health Organization; 2020.

6) Pak A, Adegboye Oa, Adekunle Ai, Rahman Km, Mcbryde Es, Eisen Dp. Economic Consequences Of The Covid-19 Outbreak: The Need For Epidemic Preparedness. Front Public Health. 2020. Https://Doi.Org/10.3389/Fpubh.2020.00241.

7) Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Et Al. Compassionate Use Of Remdesivir For Patients With Severe Covid-19. N Engl J Med. 2020;382:2327–36. Https:// Doi. Org/ 10. 1056/Nejmoa2007016(1533-4406(Electronic)).

8) Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Et Al. A Trial Of Lopinavir-Ritonavir In Adults Hospitalized With Severe Covid-19. N Engl J Med. 2020;382:1787–99 (1533–4406 (Electronic)).

9) Saber-Ayad Ma-O, Saleh Ma-O, Abu-GharbiehEa-O. The Rationale For Potential Pharmacotherapy Of Covid-19. Pharmaceuticals (Basel). 2020;13:96 (1424–8247 (Print)).

10) National Institute Of Health. Covid-19 Treatment Guidelines. 2021. Https:// Www. Covid 19tre AtmenTguidElines. Nih. Gov/ Whats-New/. Accessed 29 Jan 2021.

11) Fields, B. N.; Knipe, D. M.; Howley, P. M. Coronavirus. In Fields Virology, 6th Ed.; Wolters Kluwer Health/Lippincott Williams And Wilkins, 2013; Pp 825−858.

12) Geller, C.; Varbanov, M.; Duval, R. E. Human Coronaviruses: Insights Into Environmental Resistance And Its Influence On The Development Of New Antiseptic Strategies. Viruses 2012, 4, 3044−3068.

13) Song, Z. From Sars To Mers, Thrusting Coronaviruses Into The Spotlight. Viruses 2019, 11 (1), 59.

14) Menachery, V. D.; Graham, R. L.; Baric, R. S. Jumping Species-A Mechanism For Coronavirus Persistence And Survival. Curr. Opin. Virol. 2017, 23,1−7.

15) Who Director-General's Opening Remarks At The Media Briefing On Covid-19. In Who Newsletter; Https://Www.Who.Int/Dg/ Speeches/Detail/Who-Director-General-S-Opening-Remarks-At-Themedia-Briefing-On-Covid-19—13-April-2020. Accessed April 13, 2020.

16) Omrani, A. S.; Al-Tawfiq, J. A.; Memish, Z. A. Middle East Respiratory Syndrome Coronavirus (Mers-Cov): Animal To Human Interaction. Pathog. Global Health 2015, 109 (8), 354−62.

17) Zhou, P.; Et Al. A Pneumonia Outbreak Associated With A New Coronavirus Of Probable Bat Origin. Nature 2020, 579 (7798), 270− 273.

18) Https://Www.Nytimes.Com/2020/04/17/Opinion/Remdesivir-Coronavirus.Html

19) Stephens B (18 April 2020). "The Story Of Remdesivir". The New York Times. P. A23

20) Sheahan Tp, Sims Ac, Leist Sr, Et Al. Comparative Therapeutic Efficacy Of Remdesivir And Combination Lopinavir, Ritonavir, And Interferon Beta Against Mers-Cov. Nat Commun. 2020;11(1):222. Published 2020 Jan 10. Doi:10.1038/S41467019-13940-6

21) De Wit E, Feldmann F, Cronin J, Et Al. Prophylactic And Therapeutic Remdesivir (Gs-5734) Treatment In The Rhesus Macaque Model Of Mers-Cov Infection. Proc Natl Acad Sci U S A. 2020;117(12):6771-6776. Doi:10.1073/Pnas.1922083117

22) Agostini Ml, Andres El, Sims Ac, Et Al. Coronavirus Susceptibility To The Antiviral Remdesivir (Gs-5734) Is Mediated By The Viral Polymerase And The Proofreading Exoribonuclease. Mbio. 2018;9(2) Doi: 10.1128/Mbio.0022118.

23) Sheahan Tp, Sims Ac, Graham Rl, Et Al. Broad-Spectrum Antiviral Gs-5734 Inhibits Both Epidemic And Zoonotic Coronaviruses. Sci Transl Med. 2017;9(396) Doi: 10.1126/Scitranslmed.Aal3653.

24) Brown Aj, Won Jj, Graham Rl, DinnonKh 3rd, Sims Ac, Feng Jy, Cihlar T, Denison Mr, Baric Rs, Sheahan Tp. Broad Spectrum Antiviral Remdesivir Inhibits Human Endemic And Zoonotic Deltacoronaviruses With A Highly Divergent Rna Dependent Rna Polymerase. Antiviral Res. 2019 Sep; 169():104541.

25) Gudipati, Pavan; Biswas, Shyamasri; Goyal, Pankaj (2020): Anti Hepatitis C Viral Drugs Remdesivir And Uprifosbuvir Derivatives Are Better Inhibitors OfSars Cov2 RnadependentRna Polymerase Determined By Docking Studies. Chemrxiv. Preprint. Https://Doi.Org/10.26434/Chemrxiv.12443237.V2 .

26) Lo Mk, Jordan R, Arvey A, Et Al. Gs-5734 And Its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, And Paramyxoviruses. Sci Rep. 2017;7:43395. Published 2017 Mar 6. Doi:10.1038/Srep43395

27) Tchesnokov Ep, Feng Jy, Porter Dp, Götte M. Mechanism Of Inhibition Of Ebola Virus Rna-Dependent Rna Polymerase By Remdesivir. Viruses. 2019;11(4):326. Published 2019 Apr 4. Doi:10.3390/V11040326

28) Warren Tk Et Al., Therapeutic Efficacy Of The Small Molecule Gs-5734 Against Ebola Virus In Rhesus Monkeys. Nature. 2016 Mar 17;531(7594):381-5. Doi: 10.1038/Nature17180. Epub 2016 Mar 2. (Pubmed Id 26934220)

29) Https://Www.Drugbank.Ca/Drugs/Db01611#Reference-L8072

30) Furst De: Pharmacokinetics Of Hydroxychloroquine And Chloroquine During Treatment Of Rheumatic Diseases. Lupus. 1996 Jun;5 Suppl 1:S11-5. (Pubmed Id 8803904)

31) Https://Www.Drugbank.Ca/Drugs/Db14761#Referencel13239

32) Https://Www.Accessdata.Fda.Gov/Drugsatfda_Docs/Label/2019 /009768orig1s051lbl.Pdf

33) Furst De: Pharmacokinetics Of Hydroxychloroquine And Chloroquine During Treatment Of Rheumatic Diseases. Lupus. 1996 Jun;5 Suppl 1:S11-5. (Pubmed Id 8803904) [30] Https://Www.Ema.Europa.Eu/En/Documents/Other/Summary-Compassionate-Use-Remdesivir-Gilead_En.Pdf [31

34) Vander T, Medvedovsky M, Herishanu Y: Encephalopathy Induced By Oral Acyclovir In A Patient With Normal Renal Function. J Infect. 2003 May;46(4):286. Doi: 10.1053/Jinf.2002.1119.

35) Warren Tk, Jordan R, Lo Mk, Et Al. Therapeutic Efficacy Of The Small Molecule Gs-5734 Against Ebola Virus In Rhesus Monkeys. Nature. 2016;531(7594):381–385. Doi:10.1038/Nature17180

36) Siegel D, Hui Hc, Doerffler E, Et Al. Discovery And Synthesis Of A Phosphoramidate Prodrug Of A Pyrrolo[2,1-F][Triazin-4-Amino] Adenine C-Nucleoside (Gs-5734) For The Treatment Of Ebola And Emerging Viruses. J Med Chem. 2017;60(5):1648–1661. Doi:10.1021/Acs. Jmedchem.6b01594

37) Amirian Es, Levy Jk. Current Knowledge About The Antivirals Remdesivir (Gs-5734) And Gs-441524 As Therapeutic Options For Coronaviruses. One Health. 2020;9:100128. Doi:10.1016/J.Onehlt. 2020.100128

38) Goldman Jd, Lye Dc, Hui Ds, Et Al. Remdesivir For 5 Or 10 Days In Patients With Severe Covid-19. N Engl J Med. 2020. Doi:10.1056/ Nejmoa2015301

39) HolshueMl, Debolt C, Lindquist S, Et Al. First Case Of 2019 Novel Coronavirus In The United States. N Engl J Med. 2020;382(10):929–936. Doi:10.1056/Nejmoa2001191

40) The Covid-19 Investigation Team. First 12 Patients With Coronavirus Disease 2019 (Covid-19) In The United States. Preprint; 2020.

41) Grein J, Ohmagari N, Shin D, Et Al. Compassionate Use Of Remdesivir For Patients With Severe Covid-19. N Engl J Med. 2020;382 (24):2327–2336. Doi:10.1056/Nejmoa2007016

42) Kujawski Sa, Wong Kk, Collins Jp, Et Al. First 12 Patients With Coronavirus Disease 2019 (Covid-19) In The United States. Medrxiv; 2020.

43) LescureFx, Bouadma L, Nguyen D, Et Al. Clinical AndVirological Data Of The First Cases Of Covid-19 In Europe: A Case Series. Lancet Infect Dis. 2020;20(6):697–706. Doi:10.1016/S1473-3099 (20)30200-0

44) BeigelJh, Tomashek Km, Dodd Le, Et Al. Remdesivir For The Treatment Of Covid-19—Preliminary Report. N Engl J Med. 2020. Doi:10.1056/Nejmoa2007764.

45) Wang Y, Zhang D, Du G, Et Al. Remdesivir In Adults With Severe Covid-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet. 2020;395(10236):1569–1578. Doi:10.1016/ S0140-6736(20)31022-9

46) U.S. National Library Of Medicine Clinical Trials Registry. Coronavirus Trials. Available From: Https://Clinicaltrials.Gov/Ct2/Results?Cond=Coronavirus&Recrs=B&Recrs=A&Recrs=F&Recrs= D&Age_V=&Gndr=&Type=&Rslt=&Search=Apply. Accessed July 21, 2020.

47) National Institutes Of Health. Nih Clinical Trial Of Remdesivir To Treat Covid-19 Begins. Available From: Https://Www.Nih.Gov/News-Events/News-Releases/Nih-Clinical-Trial-Remdesivir-Treat-Covid-19- Begins. Accessed July 21, 2020. 36. U.S. National Library Of Medicine Clinical Trials Registry. Adaptive Covid-19 Treatment Trial. Available From: Https://Clinicaltrials.Gov/ Ct2/Show/Nct04280705. Accessed July 21, 2020.

48) U.S. National Library Of Medicine Clinical Trials Registry. Study To Evaluate The Safety And Antiviral Activity Of Remdesivir (Gs-5734™) In Participants With Severe Coronavirus Disease (Covid-19). Available From: Https://Clinicaltrials.Gov/Ct2/Show/Nct04292899. Accessed July 21, 2020.

49) U.S. National Library Of Medicine Clinical Trials Registry. Study To Evaluate The Safety And Antiviral Activity Of Remdesivir (Gs-5734™) In Participants With Moderate Coronavirus Disease (Covid-19) Compared To Standard Of Care Treatment. Available From: Https://Clinical Trials.Gov/Ct2/Show/Nct04292730. Accessed July 21, 2020.

50) U.S. National Library Of Medicine Clinical Trials Registry. Mild/ Moderate 2019-Ncov Remdesivir Rct; 2020. Available From: Https://Clinicaltrials.Gov/Ct2/Show/Nct04252664. Accessed July 21, 2020.

51) U.S. National Library Of Medicine Clinical Trials Registry. Severe 2019-Ncov RemdesivirRct; 2020. Available From: Https://Clinical Trials.Gov/Ct2/Show/Nct04257656. Accessed July 21, 2020